Stryker stock enters October with a Q3 results date set

Published on 10/04/2026 at 23:49 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Stryker stock was last at USD 275.43 on October 2, while its market value reached USD 105.6 billion. Q3 results are scheduled for October 29.

Isometrische Illustration der Wertschöpfungskette von Rohstoff bis Operationssaal — Isometrische 3D-Grafik zeigt die Wertschöpfungskette der Medizintechnik-Branche, in der Stryker Corp. US8636671013 tätig ist, Illustration mit AI erstellt.

Stryker Corporation stock (ISIN US8636671013) was last at USD 275.43 on the NYSE on October 2, 2026, after a 0.90 percent rise from the prior session. The next concrete company date is October 29, 2026, when Stryker will release its third quarter results and host an earnings webcast, according to StockTitan.

Second quarter growth stayed strong

Stryker's second quarter 2026 revenue was USD 6.59 billion, and adjusted earnings per share reached USD 3.69. The results were reported for the quarter ended June 30, 2026, and the adjusted EPS result increased 17.9 percent from the same quarter of 2025, according to Fortune.

The operating picture was uneven beneath the headline growth. Management said second quarter organic sales growth was 9 percent, while a Peripheral Vascular supply disruption created a backorder situation and lost sales. The company said backorders should reach a manageable level by the end of the third quarter, while elevated capital-product demand supported its second-half plans.

Guidance leaves execution in view

Stryker's fiscal 2026 outlook calls for adjusted earnings per share of USD 14.95 to USD 15.10 and organic net sales growth of 8.3 percent to 9.3 percent. The range is a key checkpoint for the October results because the company must convert its order backlog and production ramp into reported sales after the cyber-related disruption described on the earnings call.

The second quarter adjusted operating margin was 27.4 percent, 170 basis points higher than a year earlier. That improvement contrasts with the supply disruption in vascular products, making production execution and the pace of backlog reduction important variables for the next report.

Analysts keep a positive consensus

MarketBeat lists a Moderate Buy consensus from 24 analysts, including 19 Buy ratings and five Holds. Its average twelve-month price target is USD 372.64, with a high target of USD 465.00 and a low target of USD 298.00, based on the page updated October 4, 2026, according to MarketBeat.

The same analyst overview shows Stifel Nicolaus lowering its target from USD 360.00 to USD 330.00 on September 30, 2026, while retaining a Buy rating. That contrast puts the upcoming results between two signals: broad analyst support and recent target reductions.

Stock value and October results date

Stryker's market capitalization was USD 105.6 billion on October 2, 2026. The 52-week range was USD 267.00 to USD 392.55, placing the last price materially above the yearly low and below the yearly high.